Table 12Treatment discontinuation due to adverse effects with migraine preventive drugs versus placebo in children

DrugRCTs References*ChildrenRate With Drug, %Rate With Placebo, %Relative Risk (95% CI)Absolute Risk Difference (95% CI)Number Needed To Treat (95% CI)Attributable Events per 1,000 Treated (95% CI)Strength of Evidence (Reason for Lowering)
Divalproex sodium, 1,000 mg**169,731489.31.46.8 (0.9 to 54)0.08 (0.01 to 0.16)13 (7 to 111)80 (9 to 151)Low (imprecision)
Topiramate, 50-100 mg281,86,8729873.52.1 (0.7 to 6.3)0.04 (-0.02 to 0.1)NSNSLow (imprecision, medium risk of bias)
Clonidine171573.503.1 (0.1 to 73.1)0.04 (-0.06 to 0.13)NSNSInsufficient
Magnesium1741185.21.73.1 (0.3 to 29.0)0.04 (-0.03 to 0.10)NSNSLow (medium risk of bias, imprecision)

CI = confidence interval; NS = not significant (number needed to treat and number of attributable events were calculated for statistically significant differences)

*

Includes multiple publications of RCTs.

**

Bold = significant differences at 95% confidence level when 95% CI of absolute risk difference do not include 0. The entire line is bold.

Includes multiple publications of RCTs.

Bold = significant differences at 95% confidence level when 95% CI of absolute risk difference do not include 0. The entire line is bold.

From: Results

Cover of Migraine in Children: Preventive Pharmacologic Treatments
Migraine in Children: Preventive Pharmacologic Treatments [Internet].
Comparative Effectiveness Reviews, No. 108.
Shamliyan TA, Kane RL, Ramakrishnan R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.